{"nctId":"NCT02658175","briefTitle":"The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome","startDateStruct":{"date":"2015-12-23","type":"ACTUAL"},"conditions":["Familial Chylomicronemia Syndrome","Lipoprotein Lipase Deficiency","Hyperlipoproteinemia Type 1"],"count":68,"armGroups":[{"label":"Treatment-naïve Group","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]},{"label":"CS6-Volanesorsen","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]},{"label":"CS16-Volanesorsen","type":"EXPERIMENTAL","interventionNames":["Drug: Volanesorsen"]}],"interventions":[{"name":"Volanesorsen","otherNames":["IONIS-APOCIIIRx","ISIS 304801"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must give written informed consent to participate in the study (signed and dated) and any authorization required by law.\n* Able and willing to participate in a 65-week study.\n\nGroup 1 and 2:\n\n* Satisfactory completion of ISIS 304801-CS6 (NCT02211209) or ISIS 304801-CS16 (NCT02300233) index studies with an acceptable safety profile, per Sponsor and Investigator judgment.\n\nGroup 3:\n\n* Participants who did not participate in the CS6 or CS16 index studies and meet additional inclusion criteria of FCS may enroll in the study.\n* History of chylomicronemia.\n* A diagnosis of FCS (Type 1 Hyperlipoproteinemia.)\n* Fasting triglycerides greater than or equal to (≥)750 milligrams per deciliter \\[mg/dL\\] (8.4 millimoles per liter \\[mmol/L\\]) at Screening.\n\nExclusion Criteria:\n\n* Unwilling to comply with lifestyle requirements for the duration of the study.\n\nGroup 1 and 2:\n\n* Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study.\n\nGroup 3:\n\n* Diabetes mellitus if newly diagnosed or if hemoglobin A1c (HbA1c)≥ 9.0%.\n* Active pancreatitis within 4 weeks of screening.\n* Acute Coronary Syndrome within 6 months of screening.\n* Major surgery within 3 months of screening.\n* Treatment with Glybera therapy within 2 years of screening.\n* Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change From Baseline in Fasting Triglyceride (TG)","description":"Baseline for treatment-naïve group was defined as the average of open-label Day 1 pre-dose assessment and the last measurement prior to open-label Day 1. Baseline for CS6-volanesorsen and CS16-volanesorsen arm groups was defined as the average of index study Day 1 pre-dose assessment and the last measurement prior index study Day 1. The values at the Month 3 analysis time point were defined as the average of the Week 12 (Day 78) and Week 13 (Day 85) fasting assessments. The Month 6 analysis time point was at the end of Month 6, and the values were defined as the average of the Week 25 (Day 169) and Week 26 (Day 176) fasting assessments. The values at the Month 12 analysis time point were defined as the average of the Week 50 (Day 344) and Week 52 (Day 358) fasting assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.8","spread":"37.0"},{"groupId":"OG001","value":"-49.2","spread":"34.8"},{"groupId":"OG002","value":"-64.9","spread":"9.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.5","spread":"42.9"},{"groupId":"OG001","value":"-54.8","spread":"23.8"},{"groupId":"OG002","value":"-43.0","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.3","spread":"44.2"},{"groupId":"OG001","value":"-35.1","spread":"45.6"},{"groupId":"OG002","value":"-41.6","spread":"36.3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A TEAE was defined as any AE starting or getting worse on or after the first dose of the study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":51},"commonTop":["Injection site erythema","Nasopharyngitis","Injection site pain","Abdominal pain","Injection site swelling"]}}}